Takehiko Fujisawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takehiko Fujisawa has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Toshihiko Iizasa
9 shared publications- Masayuki Baba
Natl Inst Radiol Sci, Res Ctr Hosp Charged Particle Therapy, Inage Ku, Chiba 2638555, Japan
7 shared publications - Kiyoshi Shibuya
Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
6 shared publications - Kazuhiro Yasufuku
Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
5 shared publications Mitsutoshi Shiba
Department of Thoracic Surgery, Kimitsu-Chuo Hospital
5 shared publicationsMakoto Suzuki
4 shared publications
Latest Publications
- 1 January 2018
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 57 (3) , 169-176
A case of stage I nasopharyngeal carcinoma combined with stage I small cell lung cancer detected with sputum cytology during lung cancer screening
背景 : 上咽頭癌は, 本邦では年間罹患数 500 例のまれな腫瘍で, 多くは進行癌で発見される. 肺小細胞癌も早期診断が困難で, 手術施行例はまれである. 喀痰検診によりⅠ期上咽頭癌が発見され, その精査中にⅠ期肺小細胞癌が診断された 1 例を経験したので報告する. 症例 : 68 歳, 男性, 喫煙指数 900. 喀痰検診 D 判定 (高度異型細胞) にて当施設を受診. 胸部 CT 検査は陰性で, 紹介病院での気管支鏡検査でも異常所見は認められなかった. 2 年後の喀痰集検が E 判定 (癌細胞) のため, 紹介病院にて内視鏡検査を再施行し, 生検組織診を行ったところ, Ⅰ期上咽頭癌が診断された. また胸部 CT 検査にて出現した肺小結節が経過観察中に増大したため, 胸腔鏡下右中葉切除術を施行した結果, Ⅰ期肺小細胞癌の診断が得られた. 細胞像ではライトグリーン好性の異型扁平上皮細胞および癌細胞が判定に有用であった. 結論 : 喀痰細胞診と胸部 CT 検査の併用による精査および経過観察は, 重複癌の早期発見に有用であった. 喀痰細胞診では黄色調のみならずライトグリーン好性の異型細胞にも留意する必要があった. 喀痰細胞診は発見が困難な頭頸部癌の早期発見に貢献できる可能性が示唆された.
- 1 January 2018
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 57 (3) , 169-176
A case of stage I nasopharyngeal carcinoma combined with stage I small cell lung cancer detected with sputum cytology during lung cancer screening
背景 : 上咽頭癌は, 本邦では年間罹患数 500 例のまれな腫瘍で, 多くは進行癌で発見される. 肺小細胞癌も早期診断が困難で, 手術施行例はまれである. 喀痰検診によりⅠ期上咽頭癌が発見され, その精査中にⅠ期肺小細胞癌が診断された 1 例を経験したので報告する. 症例 : 68 歳, 男性, 喫煙指数 900. 喀痰検診 D 判定 (高度異型細胞) にて当施設を受診. 胸部 CT 検査は陰性で, 紹介病院での気管支鏡検査でも異常所見は認められなかった. 2 年後の喀痰集検が E 判定 (癌細胞) のため, 紹介病院にて内視鏡検査を再施行し, 生検組織診を行ったところ, Ⅰ期上咽頭癌が診断された. また胸部 CT 検査にて出現した肺小結節が経過観察中に増大したため, 胸腔鏡下右中葉切除術を施行した結果, Ⅰ期肺小細胞癌の診断が得られた. 細胞像ではライトグリーン好性の異型扁平上皮細胞および癌細胞が判定に有用であった. 結論 : 喀痰細胞診と胸部 CT 検査の併用による精査および経過観察は, 重複癌の早期発見に有用であった. 喀痰細胞診では黄色調のみならずライトグリーン好性の異型細胞にも留意する必要があった. 喀痰細胞診は発見が困難な頭頸部癌の早期発見に貢献できる可能性が示唆された.
- Open Access
- 1 January 2012
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 51 (4) , 248-255
Cytological features of peripheral type squamous cell carcinoma of the lung detected by mass screening with sputum cytology compared with central type squamous cell carcinoma
- 1 January 2012
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 51 (4) , 248-255
Open AccessCytological features of peripheral type squamous cell carcinoma of the lung detected by mass screening with sputum cytology compared with central type squamous cell carcinoma
- 26 February 2011
- Published by Bangkok Dusit Medical Service (BDMS) in The Bangkok Medical Journal
- Vol. 1 (1) , 7-9
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Followed by Thoracotomies
We described our technique for performing Endobron chial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) upon 150 patients with mediastinal lympha-denopathy using a curved linear array ultrasonic bronchoscope
- 26 February 2011
- Published by Bangkok Dusit Medical Service (BDMS) in The Bangkok Medical Journal
- Vol. 1 (1) , 7-9
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Followed by Thoracotomies
We described our technique for performing Endobron chial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) upon 150 patients with mediastinal lympha-denopathy using a curved linear array ultrasonic bronchoscope
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S790
P3-260: Chronic obstructive pulmonary disease decreases postoperative survival due to higher recurrence in male patients with stage IA lung cancer
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S790
P3-260: Chronic obstructive pulmonary disease decreases postoperative survival due to higher recurrence in male patients with stage IA lung cancer
- Open Access
- 1 June 2006
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 29 (6) , 908-913
Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?
Myasthenia gravis (MG) is an autoimmune disorder that results from dysfunction of the post-synaptic acetylcholine receptor (AchR), which may be due to reduced receptor density, increased turnover, or antibodies (AchR-Ab). Immunosuppressant therapies have been shown to suppress the destructive activity of AchR-Ab at neuromuscular junctions. Anticholinesterase inhibitors are used as a first-line medical therapy, and corticosteroids are used for patients with moderate to severe symptoms. However, anticholinesterase medications, such as pyridostigmine, do not prevent the AchR-Ab-mediated destruction of neuromuscular junctions. Furthermore, long-term use of anticholinesterases can reduce AchR responses due to the destruction of AchR, leading to increased anticholinesterase doses [1] that can suppress cardiac function [2].
- 1 June 2006
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 29 (6) , 908-913
Open AccessDoes perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?
Myasthenia gravis (MG) is an autoimmune disorder that results from dysfunction of the post-synaptic acetylcholine receptor (AchR), which may be due to reduced receptor density, increased turnover, or antibodies (AchR-Ab). Immunosuppressant therapies have been shown to suppress the destructive activity of AchR-Ab at neuromuscular junctions. Anticholinesterase inhibitors are used as a first-line medical therapy, and corticosteroids are used for patients with moderate to severe symptoms. However, anticholinesterase medications, such as pyridostigmine, do not prevent the AchR-Ab-mediated destruction of neuromuscular junctions. Furthermore, long-term use of anticholinesterases can reduce AchR responses due to the destruction of AchR, leading to increased anticholinesterase doses [1] that can suppress cardiac function [2].
- 1 October 2004
- Vol. 10 (5) , 293-6
Dramatic improvement of respiratory condition after lobectomy for localized bullous emphysema.
A case of dramatic improvement of respiratory function after lobectomy for bullous emphysema with severe hyperinflation of the left lower lobe was reported. A 72-year-old gentleman was admitted to our hospital due to increasing dyspnea with Hugh-Johns class V. His chest X-ray and computed tomography revealed a hyperinflation of the left lower lobe. Despite medication and respiratory rehabilitation, blood gas analysis showed hypercapnia and his symptoms had been progressing. Bronchofiberscopy revealed that the left lower lobe bronchi opened on inspiration and closed on expiration. Since complete destruction of the lower lobe due to air trapping was thought to be the cause of localized hyperinflation and the compression of left upper lobe, left lower lobectomy was performed. His dyspnea immediately disappeared and the respiratory function improved dramatically. We concluded that lobectomy could be considered as one of surgical options in case of complete lobar destruction in emphysema patients.
- 1 October 2004
- Vol. 10 (5) , 293-6
Dramatic improvement of respiratory condition after lobectomy for localized bullous emphysema.
A case of dramatic improvement of respiratory function after lobectomy for bullous emphysema with severe hyperinflation of the left lower lobe was reported. A 72-year-old gentleman was admitted to our hospital due to increasing dyspnea with Hugh-Johns class V. His chest X-ray and computed tomography revealed a hyperinflation of the left lower lobe. Despite medication and respiratory rehabilitation, blood gas analysis showed hypercapnia and his symptoms had been progressing. Bronchofiberscopy revealed that the left lower lobe bronchi opened on inspiration and closed on expiration. Since complete destruction of the lower lobe due to air trapping was thought to be the cause of localized hyperinflation and the compression of left upper lobe, left lower lobectomy was performed. His dyspnea immediately disappeared and the respiratory function improved dramatically. We concluded that lobectomy could be considered as one of surgical options in case of complete lobar destruction in emphysema patients.
- 15 November 2003
- Vol. 9 (15) , 5636-41
Alterations in the mitochondrial displacement loop in lung cancers.
Alterations of the noncoding displacement (D) loop of mitochondrial DNA are present in many cancers. These alterations include numerical changes in a homopolymeric C tract (PCT) at positions 303-309 and single base substitutions (SBS). We determined the frequency of D-loop alterations in lung cancer cell lines and tumors, and related them to clinicopathologic features. We sequenced the entire D-loop of 28 lung cancer cell lines [12 small cell lung cancer (SCLC) and 16 non-small cell lung cancer (NSCLC)] and matched B-lymphoblastoid cell lines. In 55 resected NSCLCs and corresponding nonmalignant lungs we determined the length of the PCT. In nonmalignant cell lines and tissues the most frequent PCT repeat number was seven (36 of 83; 43%) with a range of six to nine. Alterations, often multiple, were present in 17 of 28 (61%) of the cell lines, including 8 of 12 SCLC (67%) and 9 of 16 NSCLC (56%) lines. They consisted of SBS in 8 of 28 lines (29%), all of which were homoplasmic, and PCT changes in 14 of 28 (50%) lines, 8 of which were homoplasmic. Of interest, 95% (40 of 42) of the SBS were present within the two hypervariable regions in the D-loop. Because SBS were more frequent if PCT changes were present, only the PCT number was determined in resected samples. PCT changes were present in 11 of 55 (20%) of the NSCLC tumors. Changes were never noted in tumors when the PCT number in the nonmalignant tissue was seven, and only two tumor cell lines had changes when the PCT number in the matched lymphoblastoid cell line was seven. These changes were higher in squamous cell carcinomas (8 of 25; 32%) than in adenocarcinomas (3 of 30; 10%; P = 0.04) and in large tumors (T3 and T4; 7 of 20; 35%) compared with smaller tumors (T1 and T2; 4 of 35; 11%; P = 0.04). Smoking history, gender, age, and stage were not related to frequency of PCT change. Our findings indicate that D-loop alterations are frequent in lung cancers and their cell lines, and that these changes are weakly associated with certain clinical parameters. In tumors PCT changes were only present when the corresponding nonmalignant lung demonstrated a variation from the most common repeat number of seven.
- 15 November 2003
- Vol. 9 (15) , 5636-41
Alterations in the mitochondrial displacement loop in lung cancers.
Alterations of the noncoding displacement (D) loop of mitochondrial DNA are present in many cancers. These alterations include numerical changes in a homopolymeric C tract (PCT) at positions 303-309 and single base substitutions (SBS). We determined the frequency of D-loop alterations in lung cancer cell lines and tumors, and related them to clinicopathologic features. We sequenced the entire D-loop of 28 lung cancer cell lines [12 small cell lung cancer (SCLC) and 16 non-small cell lung cancer (NSCLC)] and matched B-lymphoblastoid cell lines. In 55 resected NSCLCs and corresponding nonmalignant lungs we determined the length of the PCT. In nonmalignant cell lines and tissues the most frequent PCT repeat number was seven (36 of 83; 43%) with a range of six to nine. Alterations, often multiple, were present in 17 of 28 (61%) of the cell lines, including 8 of 12 SCLC (67%) and 9 of 16 NSCLC (56%) lines. They consisted of SBS in 8 of 28 lines (29%), all of which were homoplasmic, and PCT changes in 14 of 28 (50%) lines, 8 of which were homoplasmic. Of interest, 95% (40 of 42) of the SBS were present within the two hypervariable regions in the D-loop. Because SBS were more frequent if PCT changes were present, only the PCT number was determined in resected samples. PCT changes were present in 11 of 55 (20%) of the NSCLC tumors. Changes were never noted in tumors when the PCT number in the nonmalignant tissue was seven, and only two tumor cell lines had changes when the PCT number in the matched lymphoblastoid cell line was seven. These changes were higher in squamous cell carcinomas (8 of 25; 32%) than in adenocarcinomas (3 of 30; 10%; P = 0.04) and in large tumors (T3 and T4; 7 of 20; 35%) compared with smaller tumors (T1 and T2; 4 of 35; 11%; P = 0.04). Smoking history, gender, age, and stage were not related to frequency of PCT change. Our findings indicate that D-loop alterations are frequent in lung cancers and their cell lines, and that these changes are weakly associated with certain clinical parameters. In tumors PCT changes were only present when the corresponding nonmalignant lung demonstrated a variation from the most common repeat number of seven.
- 15 October 2003
- Vol. 9 (13) , 4705-13
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Cell lines derived from non-small cell lung cancers (NSCLCs) revealed frequent high-level gains of chromosomal DNA at 3q23-q29 when examined by comparative genomic hybridization (CGH). Within this amplicon, a minimal common region of amplification in lung tumors had been mapped to 3q26 by earlier studies. The aim of the present work was to identify specific targets of the 3q26 amplification in NSCLCs. We examined genomic alterations in 19 NSCLC cell lines (10 derived from squamous cell carcinomas and 9 from adenocarcinomas) by using CGH and fluorescence in situ hybridization. We determined amplification and expression levels of four candidates (EVI1, TERC, SNO, and PIK3CA) in those cell lines and also in 25 primary NSCLC tumors. Because the TERC gene encodes the RNA component of human telomerase, we examined telomerase activity by the telomeric repeat amplification protocol (TRAP) assay. Copy numbers of EVI1 and TERC increased more than those of SNO and PIK3CA in our panel of NSCLC cell lines. Significant correlation between amplification and expression levels was observed only for TERC (P = 0.006), however, among these four candidate genes. Expression of TERC was also up-regulated in 24 (96%) of 25 primary NSCLC tumors compared with their nontumorous counterparts (P = 0.0001), and elevated expression of TERC was associated with high levels of telomerase activity (P = 0.048). TERC is a likely target of the 3q26 amplification, and, therefore, may be a useful biomarker for diagnosis and an attractive, novel target for molecular therapy of NSCLC.
- 15 October 2003
- Vol. 9 (13) , 4705-13
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Cell lines derived from non-small cell lung cancers (NSCLCs) revealed frequent high-level gains of chromosomal DNA at 3q23-q29 when examined by comparative genomic hybridization (CGH). Within this amplicon, a minimal common region of amplification in lung tumors had been mapped to 3q26 by earlier studies. The aim of the present work was to identify specific targets of the 3q26 amplification in NSCLCs. We examined genomic alterations in 19 NSCLC cell lines (10 derived from squamous cell carcinomas and 9 from adenocarcinomas) by using CGH and fluorescence in situ hybridization. We determined amplification and expression levels of four candidates (EVI1, TERC, SNO, and PIK3CA) in those cell lines and also in 25 primary NSCLC tumors. Because the TERC gene encodes the RNA component of human telomerase, we examined telomerase activity by the telomeric repeat amplification protocol (TRAP) assay. Copy numbers of EVI1 and TERC increased more than those of SNO and PIK3CA in our panel of NSCLC cell lines. Significant correlation between amplification and expression levels was observed only for TERC (P = 0.006), however, among these four candidate genes. Expression of TERC was also up-regulated in 24 (96%) of 25 primary NSCLC tumors compared with their nontumorous counterparts (P = 0.0001), and elevated expression of TERC was associated with high levels of telomerase activity (P = 0.048). TERC is a likely target of the 3q26 amplification, and, therefore, may be a useful biomarker for diagnosis and an attractive, novel target for molecular therapy of NSCLC.
- 1 March 2003
- Vol. 104 (3) , 305-10
[Medical education and surgical residency program for general thoracic surgery].
We introduced medical education for general thoracic surgery to medical students and a new surgical residency program to instruct residents who aspire to become general thoracic surgeons. It is important to understand the etiology of thoracic diseases, methods of diagnosis for tumorous lesions, anatomy of the interior thorax, surgical therapies and indications for thoracic diseases, and management of perioperative periods in the medical education of general thoracic surgery. According to the new residency program, a surgical resident must complete a super rotating system that consists of the subjects of internal medicine, general surgery, emergency and critical care medicine, anesthesiology, pediatrics, gynecology, and local healthcare for several months each in the first two years. On the other hand, a surgical residency program includes core surgical residencies to train clinical patient-care oriented surgeons and advanced residencies in such areas as thoracic surgery, cardiovascular surgery, pediatric surgery, and digestive organ surgery. Residents who want to become general thoracic surgeons must complete 350 cases of general surgery including at least 120 cases for an operator in the first 4 or more years in core programs. After passing the board for general surgery, they can advance to a subspecialty program for thoracic surgery in the final 3 or more years to pass the board for general thoracic surgery. It is essential to train the general thoracic surgeons who empathize with patients with thoracic diseases and can contribute to overcoming thoracic diseases by practicing evidence- or science-based medicine.
- 1 March 2003
- Vol. 104 (3) , 305-10
[Medical education and surgical residency program for general thoracic surgery].
We introduced medical education for general thoracic surgery to medical students and a new surgical residency program to instruct residents who aspire to become general thoracic surgeons. It is important to understand the etiology of thoracic diseases, methods of diagnosis for tumorous lesions, anatomy of the interior thorax, surgical therapies and indications for thoracic diseases, and management of perioperative periods in the medical education of general thoracic surgery. According to the new residency program, a surgical resident must complete a super rotating system that consists of the subjects of internal medicine, general surgery, emergency and critical care medicine, anesthesiology, pediatrics, gynecology, and local healthcare for several months each in the first two years. On the other hand, a surgical residency program includes core surgical residencies to train clinical patient-care oriented surgeons and advanced residencies in such areas as thoracic surgery, cardiovascular surgery, pediatric surgery, and digestive organ surgery. Residents who want to become general thoracic surgeons must complete 350 cases of general surgery including at least 120 cases for an operator in the first 4 or more years in core programs. After passing the board for general surgery, they can advance to a subspecialty program for thoracic surgery in the final 3 or more years to pass the board for general thoracic surgery. It is essential to train the general thoracic surgeons who empathize with patients with thoracic diseases and can contribute to overcoming thoracic diseases by practicing evidence- or science-based medicine.
- 1 August 2002
- Published by Rockefeller University Press
- Vol. 26, 15S-19S
Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer.
Cytochrome P-450 (CYP) enzymes have been shown to play important roles in chemical carcinogenesis. Reports have indicated that polymorphism in CYP1A1, CYP1A2, CYP2A6, CYP2E1, and CYP2D6 are associated with an altered risk of developing cancers of the lung, bladder, liver, and colon. CYP2E1 plays an important role in alcohol metabolism and participates in the metabolic activation of various carcinogens, such as N-nitrosodimethylamine. Recently, we found repeated sequences that consist of four alleles (A1, A2, A3, and A4) and six genotypes (A1/A2, A2/A2, A2/A3, A2/A4, A3/A4 and A4/A4) of the CYP2E1 gene. In the present study, we investigated whether these polymorphisms are associated with lung cancer and esophageal cancer. DNA was isolated from blood samples of 192 healthy control subjects, 85 patients with lung cancer, and 82 patients with esophageal cancer in Japanese males. DNA samples were amplified by polymerase chain reaction in the 5'-flanking region of the CYP2E1 gene and in exon 12 in the ALDH2 gene. The tandem repeat polymorphisms were examined using DNA fragment analysis. Missense mutations in exon 12 of the ALDH2 gene were examined using fluorescence-based single strand conformational change polymorphism analysis. Written informed consent was obtained from all the subjects. In the CYP2E1 gene 5'-flanking region polymorphism, patients with esophageal cancer showed significantly higher frequency of the A4/A4 genotype compared with the control subjects (p = 0.02), but no difference was found in patients with lung cancer. The frequencies of the mutant ALDH2*2 allele were significantly higher in patients with esophageal cancer (27.7%) than in healthy control subjects (7.3%; p< 0.0001; habitual alcohol drinkers). The distribution of genotypes and allele frequencies of the tandem repeats of the 5'-flanking region of the CYP2E1 gene was significantly different in patients with esophageal cancer.
- 1 August 2002
- Published by Rockefeller University Press
- Vol. 26, 15S-19S
Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer.
Cytochrome P-450 (CYP) enzymes have been shown to play important roles in chemical carcinogenesis. Reports have indicated that polymorphism in CYP1A1, CYP1A2, CYP2A6, CYP2E1, and CYP2D6 are associated with an altered risk of developing cancers of the lung, bladder, liver, and colon. CYP2E1 plays an important role in alcohol metabolism and participates in the metabolic activation of various carcinogens, such as N-nitrosodimethylamine. Recently, we found repeated sequences that consist of four alleles (A1, A2, A3, and A4) and six genotypes (A1/A2, A2/A2, A2/A3, A2/A4, A3/A4 and A4/A4) of the CYP2E1 gene. In the present study, we investigated whether these polymorphisms are associated with lung cancer and esophageal cancer. DNA was isolated from blood samples of 192 healthy control subjects, 85 patients with lung cancer, and 82 patients with esophageal cancer in Japanese males. DNA samples were amplified by polymerase chain reaction in the 5'-flanking region of the CYP2E1 gene and in exon 12 in the ALDH2 gene. The tandem repeat polymorphisms were examined using DNA fragment analysis. Missense mutations in exon 12 of the ALDH2 gene were examined using fluorescence-based single strand conformational change polymorphism analysis. Written informed consent was obtained from all the subjects. In the CYP2E1 gene 5'-flanking region polymorphism, patients with esophageal cancer showed significantly higher frequency of the A4/A4 genotype compared with the control subjects (p = 0.02), but no difference was found in patients with lung cancer. The frequencies of the mutant ALDH2*2 allele were significantly higher in patients with esophageal cancer (27.7%) than in healthy control subjects (7.3%; p< 0.0001; habitual alcohol drinkers). The distribution of genotypes and allele frequencies of the tandem repeats of the 5'-flanking region of the CYP2E1 gene was significantly different in patients with esophageal cancer.